>>So what do you think of the deal?<<
Well, a lot of it probably depends on what you think about SPPI as a stock and a company. (Disclaimer: I don't follow them. I seem to recall that mskatie did?)
>>Spectrum will pay to Altair an upfront payment of 100,000 shares of restricted Spectrum common stock and will make an equity investment of $200,000 for 38,314 shares of Altair common stock. In addition, Altair is eligible to receive payments upon achievement of a clinical development and certain regulatory and sales milestones, in addition to royalties on potential net sales. Additional financial details were not disclosed.<<
$200,000 in cash up front seems minimal, and Altair would be very dependent on SPPI to do well for those 100,000 sh of restricted stock to be worth a lot. Will Altair or SPPI be doing the development that the milestone payments are based on?
------
Many patients receiving kidney dialysis are poor patients relying on Medicaid. What drugs Medicaid is willing to pay for is worth paying attention too, and does not always include the latest drugs. There are older, cheaper drugs out there for this condition, but I do not recall them offhand.
However, diabetes can lead to kidney problems (and obesity can lead to diabetes), so I can easily see this as a growing problem in the U.S.
Market Data 
Markets 
AI
